Enterprise record

Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:8ec07669-672f-42e9-992a-16683ebcdddeVersion: public-1As of: unavailable

13 published Claims2 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 30, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

2 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 30, 2026

    Supports 5 claims
    • Legal Name: Milestone Pharmaceuticals Inc. · Claim reviewed: Sep 30, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 30, 2026
    • Published Fact: US · Claim reviewed: Sep 30, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 30, 2026
    • Published Fact: Biotechnology · Claim reviewed: Sep 30, 2026

  2. Milestone Pharmaceuticals Inc. DEF 14A 2025-04-30

    sec proxy · Source published: Apr 30, 2025 · Retrieved: Apr 28, 2026

    Supports 8 claims
    • Leadership Role: Andrew R. Saik: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Joseph C. Papa: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Joseph Oliveto: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Lisa M. Giles: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Michael Tomsicek: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Robert J. Wills: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Seth H.Z. Fischer: Director · Claim reviewed: Sep 30, 2026
    • Leadership Role: Stuart M. Duty: Director · Claim reviewed: Sep 30, 2026